Snapshot img

Multi-Cancer Early Detection Market Size 2025-2029

The multi-cancer early detection market size is forecast to increase by USD 1.29 billion at a CAGR of 15.4% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of cancer and the focus on developing innovative diagnostic tools. Next-generation sequencing technologies are revolutionizing the identification of cancer-related biomarkers, including DNA, RNA, and proteins, enabling the detection of genetic mutations at an early stage. However, limited insurance coverage poses a challenge to market growth. To address this, data analytics plays a crucial role in improving diagnostic accuracy and reducing healthcare costs. Biomarkers, whether DNA-based or protein-based, are essential for the early detection of various types of cancer. The market is expected to continue its expansion as advancements in technology and research lead to more accurate and cost-effective diagnostic solutions.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market is witnessing significant growth due to the increasing prevalence of cancer and the need for effective screening methods. Early detection of cancer can lead to improved patient survival rates and reduced mortality. Several technological advancements are driving the market. These include the use of nanotechnology for enhancing the sensitivity and specificity of diagnostic tools, big data analytics for identifying cancer-related biomarkers, and machine learning algorithms for analyzing genomic and proteomic data. Next-generation sequencing technologies, such as genome sequencing and RNA sequencing, are playing a crucial role in the discovery of genetic mutations associated with various types of cancer.
Liquid biopsies, which involve the analysis of DNA, RNA, and proteins present in bodily fluids, are gaining popularity as non-invasive screening methods for early cancer detection. Molecular signatures derived from genomic, proteomic, and biomarker data are being used to develop diagnostic tools for multi-cancer screening. These tools offer the potential for personalized treatment plans based on an individual's unique genetic profile. The integration of data from various sources, including electronic health records and wearable devices, is facilitating the development of more accurate and comprehensive diagnostic tools. This data can be analyzed using advanced data analytics techniques to identify patterns and trends that may indicate the presence of cancer.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Gene panel
  LDT
  Liquid biopsy
  Others


End-user

  Hospitals
  Diagnostic laboratories
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy
    Spain


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Type Insights

The gene panel segment is estimated to witness significant growth during the forecast period.

In the realm of preventive healthcare, biotechnology firms are making significant strides in the market through breakthrough device designs. Gene panel testing is a vital segment of this industry, focusing on the analysis of specific genes to identify mutations linked to various cancer types. These panels play a crucial role in personalized cancer screening and prevention by targeting inherited gene alterations. Predictive genetic testing is a key application of gene panel testing. This testing assesses inherited mutations in individuals with a family history of cancer, such as BRCA1 and BRCA2 gene mutations, which increase the risk of breast, ovarian, and other cancers.

Similarly, Lynch syndrome testing identifies mutations in mismatch repair (MMR) genes, linked to colorectal and endometrial cancers. Biotechnology companies securing venture capital investments and collaborating with national screening programs are advancing precision medicine in cancer screening. This approach tailors treatment plans based on an individual's unique genetic makeup, enhancing overall patient care. Genome science is at the forefront of these advancements, offering a more targeted and effective approach to cancer prevention and early detection. In the US market, insurance coverage for gene panel testing is expanding, making these tests more accessible to a broader population. This trend is expected to fuel the growth of the market in the coming years.

Get a glance at the market report of share of various segments Request Free Sample

The Gene panel segment was valued at USD 232.70 million in 2019 and showed a gradual increase during the foreca

The Pituitary and Lung Cancer Diagnostics Market is Segmented by Diagnostic Type (Diagnostic Imaging Tests, Biopsy and Cytology Tests, Tumor Biomarkers, and Other Diagnostic Types), Application (Breast Cancer, Lung Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, and Other Applications) and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market Size and Value (in USD) for the Above Segments.

The global non-invasive cancer detection market is projected to reach a value of USD xxx million by 2033, exhibiting a CAGR of xx% during the forecast period (2025-2033). This growth is attributed to the increasing prevalence of cancer, rising demand for early and accurate cancer detection methods, technological advancements, and government initiatives to promote cancer screening programs. Key drivers of the market include the rising incidence of cancer, the growing awareness of non-invasive cancer detection techniques, and the increasing adoption of advanced technologies such as artificial intelligence (AI) and machine learning (ML) in cancer diagnostics. The market is segmented based on type, application, and region. By type, the market is divided into imaging tests, nuclear medicine tests, and others. By application, the market is segmented into prostate cancer, bladder cancer, pancreatic cancer, breast cancer, gastric cancer, and others. Geographically, the market is analyzed across North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America is expected to hold the largest market share due to the presence of well-established healthcare infrastructure, high healthcare expenditure, and the increasing adoption of non-invasive cancer detection technologies. Asia Pacific is anticipated to witness the fastest growth rate during the forecast period owing to the rising incidence of cancer, increasing healthcare awareness, and government initiatives to improve healthcare access in developing countries.

The global cancer diagnostics market size is estimated to be USD 156 billion in 2024 and is expected to reach USD 319 billion by 2032, at a CAGR of 9.3% till 2032.

The size and share of the market is categorized based on Application (Cancer Research Centers, Cancer Hospital, Surgical Centers, Clinics) and Product (Instruments, Consumables) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The global cancer cell market size was valued at USD XX million in 2025 and is projected to expand at a CAGR of XX% from 2025 to 2033. The increasing prevalence of cancer worldwide, the growing demand for personalized medicine, and the advancements in cell culture and isolation techniques are key factors driving the growth of this market. Furthermore, the increasing government funding for cancer research and the rising adoption of cell-based therapies are further contributing to the market's expansion. The market is segmented based on application into research, diagnostics, and therapeutics. The research segment is expected to dominate the market throughout the forecast period due to the increasing demand for cancer cells for in vitro and in vivo studies. Additionally, the diagnostics segment is anticipated to grow at a significant rate owing to the rising adoption of liquid biopsy and other cell-based diagnostic techniques. Moreover, the therapeutics segment is projected to witness steady growth, driven by the development and commercialization of cell-based therapies for cancer treatment. Key players in the cancer cell market include Thermo Fisher Scientific, Abbott, Bio-Rad, GE Healthcare, Merck Millipore, and QIAGEN, among others. These companies are actively engaged in research and development, partnerships, and acquisitions to strengthen their market position and expand their product offerings. The market is expected to witness significant growth in the Asia-Pacific region over the forecast period due to the increasing incidence of cancer, government initiatives, and the presence of a large population base.

The global breast cancer screening tests market was valued at US$ 1.9 Billion in 2022 and is expected to reach US$ 4.4 Billion by 2033. The imaging tests segment with around 54.3% value share, has topped the global market within the product category in 2022 and is expected to grow at a CAGR of close to 7.8% over the forecast period (2023 to 2033).

Report Scope as Per Breast Cancer Screening Test Industry Analysis

Snapshot img

Cancer Diagnostics Market Size 2024-2028

The cancer diagnostics market size is forecast to increase by USD 17.74 billion at a CAGR of 13.64% between 2023 and 2028.

The market is experiencing significant growth due to the increasing prevalence of cancer and the advancements in medical diagnostics. Precision medicine, which utilizes genetic testing and biomarkers to tailor treatment plans, is a key trend driving market growth. Technological innovations, such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and in vitro diagnostic (IVD) testing, are revolutionizing cancer diagnosis. However, the high cost of developing companion diagnostics, which are tests used in conjunction with specific therapies, poses a challenge to market growth. The use of SPECT and MRI in cancer diagnosis is also gaining traction, while blood grouping reagents continue to play a crucial role in ensuring the compatibility of donor and recipient blood in cancer treatments.

What will be the Size of the Cancer Diagnostics Market During the Forecast Period?

Request Free Sample

The market encompasses a range of diagnostic tools and services used to identify various types of cancer in patients. This market is driven by the increasing incidence of cancer worldwide and the growing demand for early and accurate diagnosis. Private diagnostic laboratories and centers play a significant role in providing diagnostic services, offering a wide range of diagnostic imaging procedures, laboratory tests, and screening types. These include colorectal cancer screening, which is a critical area of focus due to its high prevalence and the availability of effective screening methods. Advancements in technology continue to shape the market, with a focus on the development of new biomarkers, proteins, and diagnostic testing methods for detecting cancerous tumors at an early stage.
Consumables, such as reagents and assay kits, are also a key component of the market, enabling the accurate and efficient processing of diagnostic samples. Cancer patients undergo various diagnostic procedures to assess disease progression and determine the most effective treatment options. Diagnostic testing methods include MRD testing, which provides valuable information on minimal residual disease, and tests for various types of cancer, such as skin cancer, kidney cancer, pancreatic cancer, ovarian cancer, and liver cancer. The market is expected to continue growing as advancements in technology and increased awareness of the importance of early diagnosis drive demand for more accurate and accessible diagnostic solutions.

How is this Cancer Diagnostics Industry segmented and which is the largest segment?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Hospitals and clinics
  Diagnostic laboratories


Type

  IVD
  Imaging
  LDT


Geography

  North America

    Canada
    US


  Europe

    Germany
    France


  APAC

    China


  Rest of World (ROW)

By End-user Insights

The hospitals and clinics segment is estimated to witness significant growth during the forecast period.

The market experienced significant growth in 2023, driven by the increasing incidence of various types of cancer, including cervical, head and neck, lung, skin, and colorectal cancer. Hospitals served as the primary revenue contributors due to the rising number of cancer cases and the availability of skilled professionals. Diagnostic imaging procedures, such as X-rays, ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography, and optical imaging, play a crucial role in cancer diagnosis. Private diagnostic laboratories and centers also contributed to market growth, offering advanced technology-driven diagnostic tests, including IVD testing, tumor biopsy, endoscopic examination, and genetic testing.

Early detection through cancer screening procedures, such as colorectal cancer screening, prostate cancer, and breast cancer, significantly impacted market growth. Consumables, technology, and screening types were the major segments of the market. The mortality rate of cancer patients and public awareness of cancer screening procedures further fueled market growth. Cancer diagnostic testing aids in disease progression assessment and treatment outcomes. Alcohol use, tobacco use, unhealthy lifestyle, diabetes, and other factors contribute to the increasing incidence of cancer.

Get a glance at the market report of share of various segments Request Free Sample

The Hospitals and clinics segment was valued at USD 6.71 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is est

The U.S. liver cancer diagnostics market, valued at $3.38 billion in 2025, is projected to grow at a CAGR of 4.4% during the forecast period 2025-2033. The market growth is primarily driven by the increasing prevalence of liver cancer, technological advancements in diagnostic techniques, and the rising demand for minimally invasive procedures. Rising awareness of liver cancer and the availability of advanced diagnostic tools are also contributing to market expansion. Key market trends include the increasing adoption of biomarker-based tests, such as circulating tumor cells (CTCs) and microRNAs, which offer improved sensitivity and specificity in liver cancer detection. Advancements in imaging techniques, such as multi-parametric magnetic resonance imaging (mpMRI) and contrast-enhanced ultrasound (CEUS), are also contributing to enhanced diagnostic accuracy. Additionally, the growing use of laparoscopic and robotic-assisted surgeries is driving the demand for intraoperative imaging technologies that can provide real-time visualization during liver cancer procedures. Recent developments include: In October 2023, Qiagen collaborated with Myriad Genetics to develop and commercialize laboratory-developed cancer test kits for the U.S. market. , In December 2022, Integrated DNA Technologies (IDT) acquired ArcherDX's Next Generation Sequencing (NGS) research assays from Invitae Corporation, making a significant move in the genomics and molecular biology industry as IDT expanded its portfolio to include ArcherDX's innovative NGS technologies. , In November 2019, Exact Sciences, a company specializing in cancer screening tests, acquired Genomic Health to broaden its offerings in comprehensive genomic profiling and expand its presence in the oncology market. .

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy. Read More

[230+ Pages Report] The global non-invasive cancer diagnostics market size is expected to grow from USD 139.06 billion in 2022 to USD 247.38 billion by 2030, at a CAGR of 7.80% from 2023-2030

The diagnosis of prostate cancer using histopathology is reliant on the accurate interpretation of stained or labelled tissue sections. Current standards rely on assessment following Haematoxylin and Eosin (H&E) staining, which is often difficult to interpret and introduces inter-observer variability. Here, we present a digital pathology atlas for prostate cancer tissue, using micrographs of both H&E and our novel set of three biomarkers as an interactive tool, where clinicians and scientists can explore high resolution histopathology from various case studies. The digital pathology prostate cancer atlas when used in conjunction with the biomarkers, will greatly assist pathologists to accurately grade prostate cancer tissue samples. This repository also contains the original image dataset used to generate the case studies for the digital pathology atlas. The data consist of a benign case and cases of ISUP grades from 1 to 5, where initial grading was performed on the hematoxyli..., All images were acquired using a Carl ZEISS AxioScan.Z1 microscope, with a Planapochromat 40x/0.95 objective. Images were orginially stored in the native Carl ZEISS Image format (*.CZI), and then converted to BigTIFF format using Carl ZEISS Zen Blue Software (version 3.8). Lossless compression was also used to minimise file sizes, while retaining image quality. All images can be using freely available imaging software, such as ImageJ or FiJi., , # Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers

https://doi.org/10.5061/dryad.v9s4mw749

We present a digital pathology atlas for prostate cancer tissue, using micrographs of both H&EÂ (hematoxylin and eosin) and our novel set of three biomarkers as an interactive tool, where clinicians and scientists can explore high resolution histopathology from various case studies. The digital pathology prostate cancer atlas when used in conjunction with the biomarkers, will greatly assist pathologists to accurately grade prostate cancer tissue samples. The full set of digital micrographs are also accessible in this repository, along with the grading and patient outcome data.

Description of the data and file structure

The digital pathology atlas for prostate cancer is a fully interactive portable document format (PDF) file, where users can easily explore high resolution histopathology from various case ...

The global cancer/tumor profiling pathways market size was valued at USD 5.0 billion in 2025 and is projected to reach USD 15.6 billion by 2033, exhibiting a CAGR of 14.6% during the forecast period. The growth of this market is primarily attributed to the rising incidence of cancer worldwide, technological advancements in cancer profiling techniques, and increasing adoption of personalized medicine approaches. Additionally, government initiatives to promote cancer research and the development of new cancer therapies are further driving market growth. North America dominated the global cancer/tumor profiling pathways market in 2025 and is expected to maintain its dominance throughout the forecast period. The high prevalence of cancer in the region, coupled with the presence of a large number of well-established healthcare providers and research institutions, contributes to the market's leading position. Europe and Asia Pacific are other significant markets for cancer/tumor profiling pathways, with growing awareness about cancer screening and diagnosis, as well as increasing healthcare expenditure. Key companies operating in the cancer/tumor profiling pathways market include Illumina, Inc., QIAGEN N.V., NeoGenomics Laboratories, Inc., HTG Molecular Diagnostics, Inc., and Sysmex Corporation.

Snapshot img

Breast Cancer Therapeutics Market Size 2024-2028

The breast cancer therapeutics market size is forecast to increase by USD 15.64 bn at a CAGR of 8.4% between 2023 and 2028.

The market is experiencing significant growth due to the rising prevalence of breast cancer and the emergence of novel therapeutics. Hormone therapy and radiation therapy continue to be popular treatment options, while oncology drugs such as monoclonal antibodies, biosimilars, and vaccines are gaining popularity. Artificial intelligence is revolutionizing cancer diagnostics and treatment plans, enabling early detection and personalized treatment. Online pharmacies and telemedicine are making treatments more accessible, especially in remote areas. The high cost of treatment remains a challenge, but education and nutrition programs are helping to mitigate this issue. Protein-based therapies, gelatin, and tablets are also key components of breast cancer therapeutics.In the US, the market is expected to grow steadily due to increasing awareness and advancements in technology and treatment methods.

What will be the Size of the Breast Cancer Therapeutics Market During the Forecast Period?

Request Free SampleThe market encompasses a range of treatments designed to combat this prevalent form of cancer among females. Key therapeutic approaches include chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy. Oncology drugs and therapeutics play a pivotal role in addressing breast cancer, targeting various proteins and cells, such as milk ducts, milk-producing lobules, and tumors. Breast cancer awareness initiatives and screening programs are instrumental in early detection, leading to improved patient outcomes. Artificial intelligence and advanced diagnostics are increasingly utilized to enhance the accuracy of diagnoses, enabling more effective interventions. Breast cancer can manifest as lumps, red patches, pain, swelling, or symptoms affecting the nipple, bones, breathing, or lymph nodes.Surgical tumor removal and medications, including hormonal therapies, are essential components of treatment plans. Despite advancements, breast cancer continues to pose significant health challenges, with ongoing research and innovation required to address the complexities of this disease.

How is this Breast Cancer Therapeutics Industry segmented and which is the largest segment?

The breast cancer therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. Disease TypeInvasive breast cancersDuctal carcinoma in situTherapyTargeted therapyHormonal therapyChemotherapyGeographyNorth AmericaCanadaUSEuropeGermanyUKAsiaChinaRest of World (ROW)

By Disease Type Insights

The invasive breast cancers segment is estimated to witness significant growth during the forecast period. Invasive ductal carcinoma, also known as infiltrating ductal carcinoma, is the most prevalent type of breast cancer, accounting for approximately 80% of diagnoses. This form of cancer arises when cancerous cells invade the fibrous or fatty tissue of the breast beyond the milk ducts. Symptoms include breast swelling, skin irritation, pain, nipple discomfort, redness, and nipple discharge, among others. Risk factors include genetics, hormonal imbalances, obesity, alcohol intake, and prior radiation therapy. Hormonal therapies, such as tamoxifen and aromatase inhibitors, chemotherapy, radiation therapy, targeted therapies, including Herceptin for HER2-positive tumors, and immunotherapies are common treatments. Early detection through breast cancer awareness campaigns, screening programs, and regular self-examinations contribute to improved survival probabilities and reduced morbidity.The development of oncology drugs and therapeutics, including proteins and biosimilars, continues to advance treatment options. Government support, hospital visits, and recovery rates are crucial aspects of breast cancer care. Hormonal therapy, obesity, and family history are significant factors in cancer type analysis. Hospital pharmacies and online pharmacies provide access to medications.

Get a glance at the market report of various segments Request Free Sample

The Invasive breast cancers segment was valued at USD 22.55 bn in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The North American the market is experiencing significant growth due to the availability of r

Abstract: The Cancer Genome Atlas (TCGA) was a large-scale collaborative project initiated by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). It aimed to comprehensively characterize the genomic and molecular landscape of various cancer types. This dataset includes curated survival data from the Pan-cancer Atlas paper titled "An Integrated TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR) to drive high quality survival outcome analytics". The paper highlights four types of carefully curated survival endpoints, and recommends the use of the endpoints of OS, PFI, DFI, and DSS for each TCGA cancer type. The dataset also includes phenotypic information about HNSC. The Sample IDs are unique identifiers, which can be paired with the gene expression dataset. Inspiration: This dataset was uploaded to UBRITE for GTKB project. Instruction: The survival and phenotype data were merged into one file. Empty columns were removed. Columns with the same value for every sample were also removed. Acknowledgments: Goldman, M.J., Craft, B., Hastie, M. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol (2020). https://doi.org/10.1038/s41587-020-0546-8 Liu, Jianfang, Caesar-Johnson, Samantha J. et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, Volume 173, Issue 2, 400 - 416.e11. https://doi.org/10.1016/j.cell.2018.02.052 The Cancer Genome Atlas Research Network., Weinstein, J., Collisson, E. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45, 1113–1120 (2013). https://doi.org/10.1038/ng.2764 U-BRITE last update: 07/13/2023 {"references": ["Goldman, M.J., Craft, B., Hastie, M. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol (2020). https://doi.org/10.1038/s41587-020-0546-8", "Liu, Jianfang, Caesar-Johnson, Samantha J. et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, Volume 173, Issue 2, 400 - 416.e11.\u00a0https://doi.org/10.1016/j.cell.2018.02.052", "The Cancer Genome Atlas Research Network., Weinstein, J., Collisson, E. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45, 1113\u20131120 (2013). https://doi.org/10.1038/ng.2764"]} UBRITE location: /data/project/ubrite/gtkb/TCGA/Clinical

The global cancer-focused genetic testing service market size is likely to reach a valuation of USD 8,472.70 million by 2024. A CAGR of 8.6% is estimated between 2024 and 2034. The ecosystem is set to reach USD 19.3 billion by the end of 2034.

Semi-annual Industry Updates

Country-wise Insights

Category-wise Insights

The Breast Cancer Liquid Biopsy Market is expected to reach USD 1,723.54 million by 2028, growing at a CAGR of 18.06%. This expansion is driven by advancements in cancer diagnostics, increasing awareness of liquid biopsy techniques, and the rising adoption of personalized medicine. Liquid biopsies provide a minimally invasive alternative to traditional tissue biopsies, offering higher sensitivity, faster results, and real-time monitoring of treatment responses. The growing emphasis on early cancer detection, targeted therapies, and precision medicine is further fueling market demand. Technological innovations and increased research in circulating tumor DNA (ctDNA) and biomarker analysis will continue shaping the market’s growth. Key drivers for this market are: Technological Advancements in Liquid Biopsy Techniques Rising Adoption of Personalized Medicine Government Funding and Support High Prevalence of Breast Cancer Worldwide. Potential restraints include: Cost-effectiveness and Reimbursement Concerns Limited Sensitivity and Specificity of Current Assays Regulatory Hurdles for Market Approval of New Technologies. Notable trends are: The development of novel liquid biopsy technologies and advancements in genomic sequencing have significantly enhanced the accuracy and sensitivity of liquid biopsies. Liquid biopsies play a crucial role in personalized medicine, enabling tailored treatment based on patient-specific genetic profiles. Government funding and support for cancer research, particularly in the field of liquid biopsies, have fueled market growth. The increasing incidence of breast cancer is expected to drive market demand for liquid biopsies..

The global Cancer Diagnostics market size reached USD 140.20 Billion in 2022 and is expected to reach USD 311.19 Billion in 2032 registering a CAGR of 8.3%. Cancer Diagnostics market growth is primarily driven owing to implementation of advanced molecular diagnostic techniques for early detection and diagnosis of cancers

The Cancer Profiling Market is Segmented by Technology (Immunoassays, Next Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Microarrays, and Others), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, and Others), Biomarker Type (Genetic Biomarkers, Protein Biomarkers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

The metastatic cancer treatment market is segmented by Treatment Type (Chemotherapy, Immunotherapy, Hormone Therapy, and Other Therapies), Type of Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Colorectal Cancer, and Other Type of Cancer), End Users (Hospitals, Clinics, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments.